Chikungunya Fever – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Chikungunya Fever – Pipeline Review, H1 2017’, provides an overview of the Chikungunya Fever pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chikungunya Fever, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chikungunya Fever and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Chikungunya Fever

The report reviews pipeline therapeutics for Chikungunya Fever by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Chikungunya Fever therapeutics and enlists all their major and minor projects

The report assesses Chikungunya Fever therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Chikungunya Fever

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Chikungunya Fever

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Chikungunya Fever pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Abivax SA

Arbovax Inc

Arno Therapeutics Inc

Bharat Biotech International Ltd

Ennaid Therapeutics LLC

Etubics Corp

Griffith University

Hawaii Biotech Inc

Indian Immunologicals Ltd

Inovio Pharmaceuticals Inc

Integral Molecular Inc

Integrated BioTherapeutics Inc

Merck & Co Inc

Mymetics Corp

Nanotherapeutics Inc

PaxVax Inc

Profectus BioSciences Inc

Shionogi & Co Ltd

Takeda Pharmaceutical Company Ltd

Themis Bioscience GmbH

Theravectys SA

Valneva SE

Vaxart Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Chikungunya Fever - Overview

Chikungunya Fever - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Chikungunya Fever - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Chikungunya Fever - Companies Involved in Therapeutics Development

Abivax SA

Arbovax Inc

Arno Therapeutics Inc

Bharat Biotech International Ltd

Ennaid Therapeutics LLC

Etubics Corp

Griffith University

Hawaii Biotech Inc

Indian Immunologicals Ltd

Inovio Pharmaceuticals Inc

Integral Molecular Inc

Integrated BioTherapeutics Inc

Merck & Co Inc

Mymetics Corp

Nanotherapeutics Inc

PaxVax Inc

Profectus BioSciences Inc

Shionogi & Co Ltd

Takeda Pharmaceutical Company Ltd

Themis Bioscience GmbH

Theravectys SA

Valneva SE

Vaxart Inc

Chikungunya Fever - Drug Profiles

(chikungunya + Zika) (bivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ABX-1089 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ABX-1091 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ABX-311 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AR-12 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BBV-87 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

chikungunya (viral like particles) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

chikungunya (viral like particles) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

chikungunya (virus like particle) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

chikungunya vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

chikungunya vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

chikungunya vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

chikungunya vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

chikungunya vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

chikungunya vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

chikungunya vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

chikungunya vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

chikungunya vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

chikungunya vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

chikungunya vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

chikungunya vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

chikungunya vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

chikungunya vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

chikungunya vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy for Chikungunya - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HSRx-431 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMCKV-063 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies for Chikungunya - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies for Equine Encephalitis and Chikungunya - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit CHIKV E2 for Chikungunya - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Target Viral E1 and E2 Proteins for Chikungunya and Ross River Virus Fever - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mRNA-1388 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MV-CHIK - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides for Infectious Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SCV-305 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit NS2 and NS3 for Chikungunya - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit NS4 for Chikungunya Fever - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Chikungunya - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Chikungunya - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Chikungunya Fever - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Infectious Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides for Chikungunya - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAK-507 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tatbeclin-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VLA-1553 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chikungunya Fever - Dormant Projects

Chikungunya Fever - Product Development Milestones

Featured News & Press Releases

Jan 09, 2017: Profectus BioSciences Bivalent Vaccine Protects Animals from Infection and Death After Exposure to Chikungunya or Zika Virus

Dec 19, 2016: UTMB researchers develop first chikungunya vaccine from virus that does not affect people

Aug 30, 2016: Hawaii Biotech Awarded Grant To Develop Chikungunya Virus Vaccine

Aug 25, 2016: Leading Chikungunya Vaccine in Clinical Trial Phase 2

Mar 22, 2016: Inovio’s DNA-based Monoclonal Antibody and DNA Vaccine Provide 100% Protection Against Lethal Chikungunya Virus Challenge in Preclinical Study

Sep 19, 2015: Arno Therapeutics Data Demonstrates Novel Antimicrobial Activity of AR-12, Identified it as Lead Compound of New Class of Drugs

Mar 02, 2015: Themis Bioscience’s Chikungunya Vaccine Study Results Published in The Lancet Infectious Diseases

Dec 10, 2014: Integral Molecular identifies potent inhibitory antibodies against Chikungunya virus

Nov 20, 2014: Themis Bioscience’s Vaccine Against Chikunguya Successful In Phase 1

Aug 14, 2014: Experimental chikungunya vaccine induces robust antibody response

Jun 12, 2014: Threat of Emerging Virus can be Stopped: Interim results of First Clinical Trial of Themis Bioscience's Vaccine Candidate Against Chikungunya Fever Prove Successful

Mar 27, 2013: Themis Bioscience Plans To Initiate Phase I Study Of Chikungunya Fever Vaccine Candidate

Dec 20, 2011: NIAID Enrolls Participants In Chikungunya Vaccine Trial

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Chikungunya Fever, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Chikungunya Fever – Pipeline by Abivax SA, H1 2017

Chikungunya Fever – Pipeline by Arbovax Inc, H1 2017

Chikungunya Fever – Pipeline by Arno Therapeutics Inc, H1 2017

Chikungunya Fever – Pipeline by Bharat Biotech International Ltd, H1 2017

Chikungunya Fever – Pipeline by Ennaid Therapeutics LLC, H1 2017

Chikungunya Fever – Pipeline by Etubics Corp, H1 2017

Chikungunya Fever – Pipeline by Griffith University, H1 2017

Chikungunya Fever – Pipeline by Hawaii Biotech Inc, H1 2017

Chikungunya Fever – Pipeline by Indian Immunologicals Ltd, H1 2017

Chikungunya Fever – Pipeline by Inovio Pharmaceuticals Inc, H1 2017

Chikungunya Fever – Pipeline by Integral Molecular Inc, H1 2017

Chikungunya Fever – Pipeline by Integrated BioTherapeutics Inc, H1 2017

Chikungunya Fever – Pipeline by Merck & Co Inc, H1 2017

Chikungunya Fever – Pipeline by Mymetics Corp, H1 2017

Chikungunya Fever – Pipeline by Nanotherapeutics Inc, H1 2017

Chikungunya Fever – Pipeline by PaxVax Inc, H1 2017

Chikungunya Fever – Pipeline by Profectus BioSciences Inc, H1 2017

Chikungunya Fever – Pipeline by Shionogi & Co Ltd, H1 2017

Chikungunya Fever – Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017

Chikungunya Fever – Pipeline by Themis Bioscience GmbH, H1 2017

Chikungunya Fever – Pipeline by Theravectys SA, H1 2017

Chikungunya Fever – Pipeline by Valneva SE, H1 2017

Chikungunya Fever – Pipeline by Vaxart Inc, H1 2017

Chikungunya Fever – Dormant Projects, H1 2017

List of Figures

List of Figures

Number of Products under Development for Chikungunya Fever, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports